These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

972 related items for PubMed ID: 29258369

  • 1. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).
    Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T.
    Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
    [Abstract] [Full Text] [Related]

  • 2. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
    Bor R, Fábián A, Matuz M, Szepes Z, Farkas K, Miheller P, Szamosi T, Vincze Á, Rutka M, Szántó K, Bálint A, Nagy F, Milassin Á, Tóth T, Zsigmond F, Bajor J, Müllner K, Lakner L, Papp M, Salamon Á, Horváth G, Sarang K, Schäfer E, Sarlós P, Palatka K, Molnár T.
    Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
    [Abstract] [Full Text] [Related]

  • 3. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
    Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT.
    Inflamm Bowel Dis; 2018 Mar 19; 24(4):849-860. PubMed ID: 29562271
    [Abstract] [Full Text] [Related]

  • 4. Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.
    Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T.
    Biologicals; 2019 Mar 19; 58():50-56. PubMed ID: 30755369
    [Abstract] [Full Text] [Related]

  • 5. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
    Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH, Gutierrez AM, Ciorba MA.
    J Crohns Colitis; 2016 Apr 19; 10(4):402-9. PubMed ID: 26681763
    [Abstract] [Full Text] [Related]

  • 6. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
    Schneider AM, Weghuber D, Hetzer B, Entenmann A, Müller T, Zimmermann G, Schütz S, Huber WD, Pichler J.
    BMC Gastroenterol; 2018 Sep 15; 18(1):140. PubMed ID: 30219028
    [Abstract] [Full Text] [Related]

  • 7. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW.
    J Crohns Colitis; 2019 Sep 19; 13(9):1111-1120. PubMed ID: 30768123
    [Abstract] [Full Text] [Related]

  • 8. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.
    Noman M, Ferrante M, Bisschops R, De Hertogh G, Van den Broeck K, Rans K, Rutgeerts P, Vermeire S, Van Assche G.
    J Crohns Colitis; 2017 Sep 01; 11(9):1085-1089. PubMed ID: 28369329
    [Abstract] [Full Text] [Related]

  • 9. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N, Rabizadeh S, Jossen J, Pittman N, Check M, Hashemi G, Phan BL, Hyams JS, Dubinsky MC.
    Inflamm Bowel Dis; 2016 Sep 01; 22(9):2121-6. PubMed ID: 27542130
    [Abstract] [Full Text] [Related]

  • 10. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
    Löwenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, de Vries A, van der Woude CJ, Berends S, Ambarus CA, Mathot R, Clasquin E, Baert F, D'Haens G.
    Gastroenterology; 2019 Oct 01; 157(4):997-1006.e6. PubMed ID: 31175865
    [Abstract] [Full Text] [Related]

  • 11. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
    Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y, OBSERV-IBD study group, the GETAID.
    Aliment Pharmacol Ther; 2019 Jul 01; 50(1):40-53. PubMed ID: 31165509
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
    Dragoni G, Bagnoli S, Le Grazie M, Campani C, Rogai F, Manetti N, Bensi C, Macrì G, Galli A, Milla M.
    J Dig Dis; 2019 May 01; 20(5):235-242. PubMed ID: 30927309
    [Abstract] [Full Text] [Related]

  • 13. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
    Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV, Sands BE, Colombel JF, Dulai PS, Ungaro R.
    Clin Gastroenterol Hepatol; 2019 Nov 01; 17(12):2497-2505.e1. PubMed ID: 30625408
    [Abstract] [Full Text] [Related]

  • 14. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
    Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Medici A, Forti G, Franceschi M, Ferronato A, Gallina S, Grasso G, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino' S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Scorza S, Zampaletta C, Picchio M, Elisei W.
    Eur J Intern Med; 2019 Aug 01; 66():85-91. PubMed ID: 31208827
    [Abstract] [Full Text] [Related]

  • 15. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP, GETECCU study group.
    Aliment Pharmacol Ther; 2018 Oct 01; 48(8):839-851. PubMed ID: 30281832
    [Abstract] [Full Text] [Related]

  • 16. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
    Scribano ML.
    World J Gastroenterol; 2018 Jun 21; 24(23):2457-2467. PubMed ID: 29930467
    [Abstract] [Full Text] [Related]

  • 17. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY.
    Perin RL, Damião AOMC, Flores C, Ludvig JC, Magro DO, Miranda EF, Moraes AC, Nones RB, Teixeira FV, Zeroncio M, Kotze PG.
    Arq Gastroenterol; 2019 Jun 21; 56(3):312-317. PubMed ID: 31633731
    [Abstract] [Full Text] [Related]

  • 18. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, Karling P, Söderman C, SWIBREG Vedolizumab Study Group, Myrelid P, Cao Y, Sjöberg D, Thörn M, Karlén P, Hertervig E, Strid H, Ludvigsson JF, Almer S, Halfvarson J.
    Scand J Gastroenterol; 2017 Jun 21; 52(6-7):722-729. PubMed ID: 28362144
    [Abstract] [Full Text] [Related]

  • 19. [Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice].
    Shapina MV, Nanaeva BA.
    Ter Arkh; 2020 Apr 27; 92(2):67-73. PubMed ID: 32598721
    [Abstract] [Full Text] [Related]

  • 20. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
    Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG.
    Gastroenterology; 2019 Oct 27; 157(4):1007-1018.e7. PubMed ID: 31279871
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.